Autoinflammatory & rare systemic diseases
Cross-national biologic treatment guidelines for FMF: a comparative analysis
Authors' conclusion
Significant multi-country disparities exist for the prescription of IL-1 inhibitors in FMF, with variations in national guidelines, drug availability and reimbursement.
Study context
- Population
- 39 countries examined via questionnaires to paediatric and adult rheumatologists and national representatives of the Clinical Practice Strategies (CLiPS) project; national FMF treatment guidelines
- Participants
- 39 countries
- Outcome
- Cross-national accessibility and reimbursement of IL-1 inhibitors in FMF treatment, and national guidelines
Methodological detailsquestionnaire survey, comparative analysis of national guidelines, Part of the Clinical Practice Strategies (CLiPS) project; guidelines retrieved from PubMed, MEDLINE, Scopus and Google Scholar without language restrictions
- Questionnaire survey
- Comparative analysis of national guidelines
- Part of the Clinical Practice Strategies (CLiPS) project; guidelines retrieved from PubMed, MEDLINE, Scopus and Google Scholar without language restrictions
Main finding
As reported in the abstract
- National guidelines obtained
- 11 of 39 countries
- EULAR 2016 recommendations used as guidelines
- 7 further countries
- Anakinra available for colchicine-resistant FMF
- 29 of 39 countries
- Anakinra covered by national health insurance
- 23 of 29 (79.3%)
- Canakinumab accessible
- 23 of 39 countries
- Canakinumab reimbursed
- 21 of 23 (91.3%)
- Additional prescription and reimbursement restrictions for bDMARDs in FMF
- 18 countries
Observational data: associations, not effects.
Original publication
Cross-national biologic treatment guidelines for FMF: a comparative analysis. Rheumatology (Oxford). Published 26 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →